Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. [electronic resource]
Producer: 20170927Description: 3763-3771 p. digitalISSN:- 1097-0142
- Adult
- Autografts
- Brentuximab Vedotin
- Consolidation Chemotherapy -- economics
- Cost-Benefit Analysis
- Disease Progression
- Health Care Costs
- Hematopoietic Stem Cell Transplantation
- Hodgkin Disease -- drug therapy
- Humans
- Immunoconjugates -- therapeutic use
- Markov Chains
- Middle Aged
- Quality of Life
- Quality-Adjusted Life Years
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.